No Detail Found!

Efectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial

Author(s)
Shehnoor Azhar 4/75-C, Askari 11, Lahore, Pakistan.
Javed Akram 4/75-C, Askari 11, Lahore, Pakistan.
Waqas Latif 4/75-C, Askari 11, Lahore, Pakistan.
Naomi Cano Ibanez 4/75-C, Askari 11, Lahore, Pakistan.
Samiullah Mumtaz 4/75-C, Askari 11, Lahore, Pakistan.
Ali Rafi 4/75-C, Askari 11, Lahore, Pakistan.
Usman Aftab 4/75-C, Askari 11, Lahore, Pakistan.
Somia Iqtadar 4/75-C, Askari 11, Lahore, Pakistan.
Muhammad Shahzad 4/75-C, Askari 11, Lahore, Pakistan.
Fibhaa Syed 4/75-C, Askari 11, Lahore, Pakistan.
Bilal Zafar 4/75-C, Askari 11, Lahore, Pakistan.
Nighat Fatima 4/75-C, Askari 11, Lahore, Pakistan.
Saleh Saadat Afridi 4/75-C, Askari 11, Lahore, Pakistan.
Shehla Javed Akram 4/75-C, Askari 11, Lahore, Pakistan.
Muhammad Afzal Chaudhary 4/75-C, Askari 11, Lahore, Pakistan.
Farah Sadiq 4/75-C, Askari 11, Lahore, Pakistan.
Saifullah Goraya 4/75-C, Askari 11, Lahore, Pakistan.
Muhammad Hanif 4/75-C, Askari 11, Lahore, Pakistan.
Verda Ashraf 4/75-C, Askari 11, Lahore, Pakistan.
Saadia Ashraf 4/75-C, Askari 11, Lahore, Pakistan.
Humaira Akram 4/75-C, Askari 11, Lahore, Pakistan.
Tanwir Khaliq 4/75-C, Askari 11, Lahore, Pakistan.
Abstract
Objective: We assessed the efectiveness of oral Hydroxychloroquine (HC), Azithromycin (AZ) and Oseltamivir (OS), alone or combined, among patients hospitalized with mildly symptomatic coronavirus infectious disease (COVID-19). Methods: Following the approval of the National Bioethics Committee and prospective registration (clinicaltrials.gov NCT04338698), a multicenter randomized clinical trial of adaptive design was conducted at 10 multispecialty hospitals in Pakistan. Patients were randomized into seven treatment groups. Starting April 15, 2020, consenting, eligible, otherwise healthy adult patients or those with co-morbidities under control, were recruited if they presented with mildly symptomatic COVID-19 (scored 3 on a 7-point ordinal scale anchored between 1 = not hospitalized, able to undertake normal activities, to 7 = death) confirmed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Two primary outcomes were assessed by day seven: Turning qRT-PCR negative; and clinical improvement of two points from the baseline. Outcome rates were compared using a chi-square test. Multiple imputations were applied to handle missing data. An interim data analysis was carried out on July 19, 2020, following which the study continued without treatment group changes. Data Safety and Monitoring Board advised to stop recruitment due to its futility on January 18, 2021. Results: Of 471 patients randomized, a total of 426 (90.4%) completed the follow-up for primary outcomes. Based on imputed data analyses at day seven: Total qRT-PCR negative cases were 137/471 (29%, 95% CI 25.0 - 33.4). By day seven, a total of 111/471 (23.5%, 95% CI 19.8 - 27.6) showed clinical improvement. No serious or non-serious adverse event was reported. Conclusions: Among patients with mild COVID-19, there was no statistically significant diference in the efectiveness of oral antimalarial, antiviral, or antibiotic treatments.
Publication Details
Page(s) 800-810
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 5, Year: 2024

Request the full text from PASTIC

Keywords
COVID-19, SARS-CoV-2, Patients, Hospitalization, Covid-19, efectiveness, follow-up
0

Citations

0

Downloads

70

Views